Abella Mar

Active

Private limited companyfounded 2019active for 6 yearsOosthoevestraat 16, 2950 Kapellen, BelgiumKBO/BCE: BE 0740.524.031

Summary

Abella Mar has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €83,881 and a net result of €8,736. Equity is growing by about 22% per year across the filed financial years. Its solvency ranks better than 59% of 74 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysisFollow Report Compare

Abella MarActiveChecked score 89/100

Risk analysis Report Compare

Activity

Manufacture of basic pharmaceutical products and pharmaceutical preparations

NACE 21100

1 site

Size

≈ €150,000turnover 2025, estimated

Equity: €83,881
Profit: €8,736

Turnover estimated from the gross margin

Financial health

89 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.2%

Structure

2025 accounts 35 days early1 of 2 deeds summarised

Why 89raises riskSize: total assets €150,376lowers riskLiquidity: current ratio 2.80, cash €20,801Sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)Equity €83,881 (55.8% of total assets)Show the evidence

Checked score

Score 2025

89 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 66% of its sector peers (NACE 21, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Strong

Solvency 81+4

equity 55.8% of total assets

Liquidity 66-6

short-term debt 11.4% · cash 13.8%

Profitability 76-4

return on assets 5.8%

Bankruptcy probability, 12 months

0.2% Very low

0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.4% (154 companies, NACE 21, micro)

Last 24 months 11-2024: 0.2% 12-2024: 0.2%● unchanged vs 11-2024 01-2025: 0.1%▼ -0.1 percentage points vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025lowest value 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.2%▲ +0.1 percentage points vs 04-2025 06-2025: 0.2%● unchanged vs 05-2025 07-2025: 0.4%▲ +0.2 percentage points vs 06-2025 08-2025: 0.4%● unchanged vs 07-2025 09-2025: 0.4%● unchanged vs 08-2025 10-2025: 0.4%● unchanged vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.5%▲ +0.1 percentage points vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.5%● unchanged vs 06-2026 08-2026: 0.6%▲ +0.1 percentage points vs 07-2026 09-2026: 0.9%▲ +0.3 percentage points vs 08-2026highest value 10-2026: 0.2%▼ -0.7 percentage points vs 09-2026

Credit of up to €7,000 on 30-day terms is acceptable

Liquidity ample (current ratio 2.8, compared with 2.23 in 2024, above the usual 1.5; short-term debt: 11.4% and cash: 13.8% of total assets), and 44.2% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro): better than 64% on solvency, 68% on liquidity, 66% on profitability and 65% on growth.

The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: current ratio 2.80, cash €20,801

NBB · annual accounts

Size: total assets €150,376

Companies of this size fail more often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)

KBO

Equity €83,881 (55.8% of total assets)

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-06-2026, 35 days ahead of the deadline.

NBB · 6 filings

Deviation from the deadline

2025

35 days early

2024

45 days early

2023

47 days early

2022

40 days early

2021

18 days early

2020

3 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 6 accounts on average 31 days before the deadline; the sector median (NACE 21) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 21 June (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

30-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

26-06-2026 Annual accounts filedfinancial year 2025 · micro…
16-06-2025 Annual accounts filedfinancial year 2024 · micro…
12-09-2024 Registered officeRegistered-office move

Key points

Positive: Always filed on timeaccounts within the deadline every year 6 years View
Positive: 6 profitable years in a rowprofit 2025: €8,736 6 years View
Total assets 20256 financial years filed €150,376 View

By topic

Financials

Financial year: 2025
Total assets: €150,376
Profit: €8,736
Solvency: 55.8%

Total assets▲ 4.8%

Net result

20202025

Go to Financials

Timeline

Events: 9
Since: 2021
Next accounts: by 31-07-2027

14-06-2024Annual accounts filed
31-12-2023Highest result from 2020 to 2025
21-06-2023Annual accounts filed

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100
Founded: 27-12-2019
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Key facts about Abella Mar

What is the company number of Abella Mar?: 0740.524.031. In Belgium the VAT number is the company number with BE in front: BE 0740.524.031.
Where is Abella Mar based?: The registered office is at Oosthoevestraat 16, 2950 Kapellen.Company details
What does Abella Mar do?: According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
What is the legal form of Abella Mar?: Private limited company (BV).
When was Abella Mar founded?: On 27-12-2019.
Is Abella Mar still active?: Yes, Abella Mar is an active enterprise in the KBO register.
What is the turnover of Abella Mar?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is Abella Mar profitable?: In financial year 2025, Abella Mar made a profit of €8,736.
Where can I find the annual accounts of Abella Mar?: Abella Mar filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Abella Mar due?: By 31-07-2027, for financial year 2026.Timeline